Novartis Ag (NVS) Cash from Investing Activities (2009 - 2025)

Novartis Ag's (NVS) quarterly Cash from Investing Activities came in at -$2.1 billion in Q4 2025, up 48.76% year-on-year from -$1.4 billion in Q4 2024, and down 144.65% quarter-over-quarter from -$860.0 million in Q3 2025.

Novartis Ag (NVS) Cash from Investing Activities (2009 - 2025) Analysis & Trends

Novartis Ag has disclosed Cash from Investing Activities across 15 years of filings, most recently posting -$2.1 billion for Q4 2025.

  • Cash from Investing Activities for Q4 2025 came in at -$2.1 billion, up 48.76% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.9 billion (up 43.2% YoY), and the FY2025 annual result was -$4.9 billion, up 35.09% from the prior year.
  • Cash from Investing Activities came in at -$2.1 billion for Q4 2025 at Novartis Ag, down from -$860.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $9.7 billion in Q4 2023 to a low of -$11.6 billion in Q2 2022.
  • The 5-year median for Cash from Investing Activities is -$899.0 million (2024), against an average of -$1.1 billion.
  • Across the five-year window, Cash from Investing Activities sank 11965.31% in 2022 and jumped 530.62% in 2023, its largest moves.
  • Novartis Ag's Cash from Investing Activities stood at $883.0 million in 2021, then sank by 356.29% to -$2.3 billion in 2022, then surged by 530.62% to $9.7 billion in 2023, then tumbled by 142.13% to -$4.1 billion in 2024, then jumped by 48.76% to -$2.1 billion in 2025.
  • The last three Cash from Investing Activities figures came in at -$2.1 billion (Q4 2025), -$860.0 million (Q3 2025), and -$2.2 billion (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -1.98 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -3.92 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -1.04 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -574.00 Mn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -10.21 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -716.00 Mn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 1.77 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 785.00 Mn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -131.00 Mn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -2.10 Bn
Dec 31, 2025 -2.10 Bn
Sep 30, 2025 -860.00 Mn
Sep 30, 2025 -860.00 Mn
Jun 30, 2025 -2.24 Bn
Jun 30, 2025 -2.24 Bn
Mar 31, 2025 330.00 Mn
Mar 31, 2025 330.00 Mn
Dec 31, 2024 -4.11 Bn
Dec 31, 2024 -4.11 Bn
Sep 30, 2024 -374.00 Mn
Sep 30, 2024 -374.00 Mn
Jun 30, 2024 -3.21 Bn
Jun 30, 2024 -3.21 Bn
Mar 31, 2024 -899.00 Mn
Mar 31, 2024 -899.00 Mn
Dec 31, 2023 9.75 Bn
Dec 31, 2023 9.75 Bn
Jun 30, 2023 -960.00 Mn
Jun 30, 2023 -960.00 Mn